R&D News | pharmaphorum

News

Nature: "Sidewinder" tech a leap forward in DNA synthesis

A new technology developed at Caltech represents a breakthrough in DNA synthesis, essentially allowing de novo sequence creation.

News

Sanofi plans amlitelimab dermatitis filing after new readout

Sanofi has said it will press ahead with regulatory filings for atopic dermatitis candidate amlitelimab, despite mixed data in phase 3.

News

Corxel's raises $287m for obesity drug, and other financings

Our latest biofinancing round-up sees big rounds for Corxel and Caldera, with Mendra, Think Bio, Exciva, Cytotheryx, and Infinitopes also raising cash

News

Ovarian cancer data restores faith in Corcept's relacorilant

After Corcept's setback with relacorilant in Cushing syndrome last month, the company has bounced back with strong survival data in ovarian cancer.

News

Man looking through red lenses of binoculars

11 high-impact drugs to look out for in 2026

Medicines for obesity, diabetes, rare diseases, cancer, and women's health feature among Clarivate's annual round-up of 11 Drugs to Watch this year.

News

Hopstem maps course to bring stem cell stroke therapy to US

China's Hopstem has been cleared to move straight to a phase 2 trial in the US for its stem cell-based therapy to aid recovery after a stroke.

Nature: "Sidewinder" tech a leap forward in DNA synthesis

Sanofi plans amlitelimab dermatitis filing after new readout

Corxel's raises $287m for obesity drug, and other financings

Ovarian cancer data restores faith in Corcept's relacorilant

11 high-impact drugs to look out for in 2026

Hopstem maps course to bring stem cell stroke therapy to US

Bayer reveals data behind asundexian's stroke win

How to meet your physicians where they are online

News

Editor's Picks